09:43:07 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-13 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-23 X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-02 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-06-02 Årsstämma 2023
2023-06-02 X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-05-04 Kvartalsrapport 2023-Q1
2023-03-24 Extra Bolagsstämma 2023
2023-03-08 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-10-03 Extra Bolagsstämma 2022
2022-08-24 Kvartalsrapport 2022-Q2
2022-06-03 X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-03-09 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksam inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2024-06-11 08:00:00

Vimian Group AB (publ)’s subsidiaries, part of Vimian’s MedTech segment, have reached a settlement agreement with one of the main sellers of Veterinary Orthopedic Implants, LLC (“VOI”). The seller has agreed to compensate Vimian for his entire pro rata share, amounting to 37 per cent, of the USD 70 million settlement payment to DePuy Synthes. The total value of the settlement amounts to approximately USD 26 million.

Following the USD 70 million settlement with DePuy Synthes in the US patent dispute in April 2023, Vimian initiated the process to retrieve compensation from the sellers of Vimian’s subsidiary VOI as per the indemnification in the purchase agreement from the acquisition of VOI (“MIPA”). In February 2024, a first settlement agreement was reached with one of the sellers. Today, a settlement agreement was reached with one of the remaining sellers.

The settlement agreement reached today implies that the seller previously owning 37 per cent of VOI, in line with the indemnification clause set out in the MIPA, takes full responsibility for his share of the DePuy Synthes settlement. The settlement corresponds to a total value of approximately USD 26 million, of which (i) approximately USD 19 million is payable in cash in eight quarterly instalments from June 2024 to January 2026, and (ii) approximately USD 7 million is contributed by means of dismissal of the contingent closing note from the acquisition of VOI.

In addition, on 3 May 2024, a settlement agreement was reached with the seller of VOI with the smallest share, in which he agreed to compensate Vimian for his entire pro rata share, amounting to 2.5 per cent, of the USD 70 million settlement payment to DePuy Synthes. The total value of the settlement with this seller of VOI amounts to approximately USD 2 million.

Vimian continues the legal process to retrieve compensation from the remaining seller (acting as an individual and via legal entity) of VOI, which is the only remaining seller in the dispute.

More background on the US patent dispute can be found in Vimian’s Annual Reports for 2022 and 2023.